Poniard Pharmaceuticals Inc. (PARD P) is in the Pharma Industry

• Sort by

• Poniard Pharmaceuticals, Inc. Q1 2008 Earnings Call Transcript

  Question-and-Answer Session Operator Operator instructions We'll take our first question from Brett Holley with Oppenheimer & Co. Michael Barrick – Oppenheimer & Co. Oh, hi. This is actually Michael Barrick [ph] on behalf of Brett. I just have a question about the colorectal cancer trial. Acknowledging...

  Earnings calls 2008-05-24

  Tags: Poniard Pharmaceuticals Inc.

• Poniard Pharmaceuticals Inc Q4 2007 Earnings Call Transcript

  Question-and-Answer SessionOperator Operator instructions We'll go first to Katherine Xu of Credit Suisse. Katherine Xu - Credit Suisse Hi, good afternoon. Jerry McMahon Good afternoon. Katherine Xu - Credit Suisse Jerry, I'm just curious, during around JPMorgan in January you said, from what your estimates,...

  Earnings calls 2008-03-17

  Tags: Poniard Pharmaceuticals Inc.

Additional Resources

• Poniard Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference

  SOUTH SAN FRANCISCO, Calif., Sept. 29 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. , a biopharmaceutical company focused on oncology, today announced that Jerry McMahon, Ph.D., chairman and CEO, will present at the JMP Securities Healthcare Focus Conference on Monday, October 6, at 9 a.m. Eastern Time at Le Parker Meridien...

  Articles 2008-09-29

• Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium

  SOUTH SAN FRANCISCO, Calif., July 31 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. , a biopharmaceutical company focused on oncology, today announced that the Company will present information on platinum resistance at the Fourth Annual Moores UCSD Cancer Center Translational Oncology Symposium on Friday, August 1, in San Diego. ...

  Articles 2008-07-31

• Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update

  - Conference Call Today at 5:00 p.m. Eastern Time - SOUTH SAN FRANCISCO, Calif., July 31 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. , a biopharmaceutical company focused on oncology, today reported on its corporate progress and financial results for the second quarter ended June 30, 2008. ...

  Articles 2008-07-31

• Poniard Pharmaceuticals Announces Upcoming Conference Participation

  SOUTH SAN FRANCISCO, Calif., July 29 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. , a biopharmaceutical company focused on oncology, today announced that Ronald A. Martell, president and chief operating officer, will participate in two upcoming conferences in August during which he will provide a corporate overview, including a discussion of...

  Articles 2008-07-29

• Poniard Pharmaceuticals to Host Second Quarter 2008 Financial Results Conference Call on July 31

  SOUTH SAN FRANCISCO, Calif., July 24 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. , a biopharmaceutical company focused on oncology, today announced that it will hold a conference call to discuss the Company's second quarter results and provide a corporate update, including an update on the clinical development plan for picoplatin,...

  Articles 2008-07-24

• Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting

  - Safety and Efficacy Clinical Data from Prostate, Colorectal and Ovarian Cancers - - Company to Hold Investor Event on Sun., June 1 with Oncology Experts - SOUTH SAN FRANCISCO, Calif., May 15 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. , a biopharmaceutical company focused on oncology,...

  Articles 2008-05-16

• Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute

  -Successful Collaboration with Scripps Florida and Scripps Research in La Jolla- SOUTH SAN FRANCISCO, Calif., and LA JOLLA, Calif., May 14 /PRNewswire- FirstCall/ -- Poniard Pharmaceuticals, Inc. , a biopharmaceutical company focused on oncology, and The Scripps Research Institute, a non-profit biomedical research organization, today announced that...

  Articles 2008-05-14

• Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update

  - Conference Call Today at 5:00 p.m. Eastern Time - SOUTH SAN FRANCISCO, Calif., May 6 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. , a biopharmaceutical company focused on oncology, today reported on its corporate progress and financial results for the first quarter ended March 31, 2008. ...

  Articles 2008-05-06

• Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer

  - Preliminary Phase 1 and 2 Data Expected at ASCO in June - SOUTH SAN FRANCISCO, Calif., May 6 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. , a biopharmaceutical company focused on oncology, today announced that it has completed patient enrollment in its Phase 2 clinical trial evaluating picoplatin...

  Articles 2008-05-06

• Poniard Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results and Corporate Update

  - Conference Call Today at 5:00 p.m. Eastern Time - SOUTH SAN FRANCISCO, Calif., Feb. 28 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. , a biopharmaceutical company focused on oncology, today reported on its corporate progress and financial results for the fourth quarter and year ended December 31, 2007....

  Articles 2008-02-28

• Poniard Pharmaceuticals to Host Fourth Quarter and Year-End 2007 Financial Results Conference Call on February 28

  SOUTH SAN FRANCISCO, Calif., Feb. 21 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. , a biopharmaceutical company focused on oncology, today announced that it will hold a conference call to discuss the Company's fourth quarter and year-end financial results and provide a corporate update, including an update on the clinical development...

  Articles 2008-02-21

• Market Review for Poniard Pharmaceuticals, Inc.

  M2 PRESSWIRE-4 February 2008-The SI Report: Market Review for Poniard Pharmaceuticals, Inc.C1994-2008 M2 COMMUNICATIONS LTD RDATE:04022008 Streetinvesting.com has now resumed our progressive review of Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), after it traded down less than 1% Monday, noon with...

  Articles 2008-02-04

• Progressive Following on Poniard Pharmaceuticals Inc.

  M2 PRESSWIRE-7 January 2008-Streetinvesting.com: Progressive Following on Poniard Pharmaceuticals IncC1994-2008 M2 COMMUNICATIONS LTD RDATE:07012008 Stocks lost ground Friday following the government's much anticipated report on the country's employment outlook which stated a weaker-than-expected job growth and a definite...

  Articles 2008-01-07

• Poniard Pharmaceuticals Provides 2008 Clinical Goals for Picoplatin.

  M2 PRESSWIRE-7 January 2008-The Maybach Financial Group: Poniard Pharmaceuticals Provides 2008 Clinical Goals for PicoplatinC1994-2008 M2 COMMUNICATIONS LTD RDATE:07012008 Maybach Financial Group is a syndicate of financial analysts, with a core group representing over 250 years of total investing...

  Articles 2008-01-07

• Poniard keeps on moving forward

  SOUTH SAN FRANCISCO, Calif. -- Poniard Pharmaceuticals Inc., a biopharmaceutical company focused on oncology, has provided an update of its picoplatin development program in small-cell lung cancer SCLC, colorectal cancer and hormone refractory prostate cancer. In a presentation at a recent health care conference chairman and chief executive...

  Articles 2007-12-17

• Molecular Insight Pharmaceuticals, Inc. Completes Strategic Purchase of Radiopharmaceutical Manufacturing Facility

  CAMBRIDGE, Mass. -- Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) announced today that it has completed the purchase of a commercial-scale radiopharmaceutical manufacturing facility located in Denton, Texas, effective October 1, 2007. Molecular Insight purchased the facility from NeoRx Manufacturing Group, Inc., a wholly owned subsidiary of Poniard...

  Articles 2007-10-03

• PONIARD PHARMACEUTICALS REPORTS 2ND QTR NET LOSS OF $8.5 MIL.(Financial report)

  Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, has reported on its corporate progress and financial results for the quarter ended June 30, 2007. "Poniard achieved significant milestones during the last quarter, including the initiation of our...

  Articles 2007-09-01

• Lt. Governor John Garamendi to Tout Bio-Technology as Key to State's Economic Future During Wednesday Meetings at Prominent South San Francisco Bio Science Facilities

  SOUTH SAN FRANCISCO, Calif. -- Lieutenant Governor John Garamendi on Wednesday will announce that he will recommend the creation of a state advisory committee on biotechnology to help support and spur the growth of California's economy. Garamendi, as chair of the newly revitalized Commission for Economic Development,...

  Articles 2007-07-31